V2food, the CSIRO-backed start-up behind Hungry Jack’s plant-based ‘Rebel Whopper’, has lost its bid to patent a product that changes colour when cooked in order to imitate the “meat experience”.
Zoetis has been ordered to pay Scidera’s costs of defending an unsuccessful summary dismissal application on a lump sum basis in a dispute over a bovine gene patent, with a judge rejecting its “premature” bid for a set-off.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
A judge has declined to order US-based animal genomics company Scidera to file a position statement in its bovine gene patent infringement suit and said she was “running out of patience” after unsuccessful strike-out and summary dismissal applications by the defendants.
Animal drug company Zoetis has lost its bid for summary dismissal of claims that it infringed US-based animal genomics company Scidera’s bovine gene patent, with a judge saying its novel arguments were not so clear-cut and needed to be worked out at trial.
Samsung Bioepis has successfully opposed Janssen’s bid to patent a monoclonal antibody to treat ulcerative colitis, but an IP Australia delegate has given the J&J-owned company a chance to fix its application.
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
A judge has ordered tech company Vehicle Management Systems to hurry up and choose between damages or an account of profits in its IP dispute with the city of Melbourne over a sensor-based system for timing parked vehicles.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
A German bottling machine manufacturer has successfully opposed PepsiCo’s patent application for a filling system, after arguing the claims were obvious.